FIELD: chemistry; pharmaceutics.
SUBSTANCE: group of inventions relates to chemical and pharmaceutical industry, namely to a liquid dosage form for oral administration for the treatment and/or prevention of flu and/or ARVI. The liquid dosage form for oral administration for the treatment and/or prevention of flu and/or ARVI contains 2-(imidazole-4-yl)ethanamide of pentanedioic-1,5 acid or its pharmaceutically acceptable salt in the effective amount and pharmaceutically acceptable auxiliary substances. In this case, the specified auxiliary substances are selected from a group including a stabilizer, a preservative, a thickener, a sweetener, a flavor and water in following amounts, wt.%: stabilizer 12.6-40.0; preservative 0-5.0; thickener 0-5.0; sweetener 0-50.0; water qs, while pH of the liquid dosage form is from 3 to 8. The liquid dosage form for oral administration for the treatment and/or prevention of flu and/or ARVI contains following substances, g per 100 ml: 2-(imidazole-4-yl)ethanamide of pentanedioic-1,5 acid 0.600; glycerin 20.610; xanthan gum 0.252; maltitol 34.350; sodium methylparahydroxybenzoate 0.177; citric acid monohydrate 0.037; flavor 0.115; purified water up to 100 ml. The use of a liquid dosage form for the treatment and/or prevention of flu and/or ARVI is also described.
EFFECT: above-described liquid form for oral administration for the treatment and/or prevention of flu and/or ARVI has high stability.
20 cl, 33 tbl, 6 ex
